How to buy ImmunoGen stock | 5.75

ImmunoGen, Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 75 staff and has a trailing 12-month revenue of around USD$86.5 million.

How to buy shares in ImmunoGen

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ImmunoGen. Find the stock by name or ticker symbol: IMGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ImmunoGen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$5.75, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ImmunoGen, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ImmunoGen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted ImmunoGen's share price?

Since the stock market crash in March caused by coronavirus, ImmunoGen's share price has had significant positive movement.

Its last market close was USD$5.75, which is 5.91% up on its pre-crash value of USD$5.41 and 194.87% up on the lowest point reached during the March crash when the shares fell as low as USD$1.95.

If you had bought USD$1,000 worth of ImmunoGen shares at the start of February 2020, those shares would have been worth USD$542.75 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,228.66.

ImmunoGen share price

Use our graph to track the performance of IMGN stocks over time.

ImmunoGen shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$5.75
52-week range	USD$1.95 - USD$6.79
50-day moving average	USD$4.126
200-day moving average	USD$4.2112
Wall St. target price	USD$8.11
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.19

Buy ImmunoGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ImmunoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ImmunoGen, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoGen price performance over time

Historical closes compared with the close of $5.75 from 2020-11-16

1 week (2020-11-24)	7.68%
1 month (2020-10-30)	1.95%
3 months (2020-09-01)	53.74%
6 months (2020-06-01)	16.87%

1 year (2019-11-29)	59.28%
2 years (2018-11-30)	4.36%
3 years (2017-12-01)	-5.58%
5 years (2015-12-01)	-56.70%

ImmunoGen financials

Revenue TTM	USD$86.5 million
Gross profit TTM	USD$-32,251,000
Return on assets TTM	-10.9%
Return on equity TTM	0%
Profit margin	-81.34%
Book value	$-0.455
Market capitalisation	USD$1.1 billion

TTM: trailing 12 months

Shorting ImmunoGen shares

There are currently 17.3 million ImmunoGen shares held short by investors – that's known as ImmunoGen's "short interest". This figure is 10.4% up from 15.7 million last month.

There are a few different ways that this level of interest in shorting ImmunoGen shares can be evaluated.

ImmunoGen's "short interest ratio" (SIR)

ImmunoGen's "short interest ratio" (SIR) is the quantity of ImmunoGen shares currently shorted divided by the average quantity of ImmunoGen shares traded daily (recently around 2.3 million). ImmunoGen's SIR currently stands at 7.54. In other words for every 100,000 ImmunoGen shares traded daily on the market, roughly 7540 shares are currently held short.

However ImmunoGen's short interest can also be evaluated against the total number of ImmunoGen shares, or, against the total number of tradable ImmunoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoGen's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 ImmunoGen shares in existence, roughly 100 shares are currently held short) or 0.1114% of the tradable shares (for every 100,000 tradable ImmunoGen shares, roughly 111 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoGen.

Find out more about how you can short ImmunoGen stock.

ImmunoGen share dividends

We're not expecting ImmunoGen to pay a dividend over the next 12 months.

ImmunoGen share price volatility

Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $1.95 up to $6.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 2.0419. This would suggest that ImmunoGen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ImmunoGen overview

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

• What percentage of ImmunoGen is owned by insiders or institutions?

  Currently 1.115% of ImmunoGen shares are held by insiders and 76.608% by institutions.

• How many people work for ImmunoGen?

  Latest data suggests 75 work at ImmunoGen.

• When does the fiscal year end for ImmunoGen?

  ImmunoGen's fiscal year ends in December.

• Where is ImmunoGen based?

  ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451

• What is ImmunoGen's ISIN number?

  ImmunoGen's international securities identification number is: US45253H1014

• What is ImmunoGen's CUSIP number?

  ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101